Cornelia Dunger-Baldauf
Prime Force Consultant Biostatistics, Novartis She has more than 30 years of experience in the pharmaceutical industry as a lead statistician in roles with increasing levels of responsibility.
About this speaker
Cornelia Dunger-Baldauf is an experienced biostatistics consultant specializing in clinical trial design and drug development. At Novartis, she has made significant contributions to research on innovative trial methodologies, including single-arm trials and augmented clinical trial designs, which aim to improve evidence generation in drug development. Her work highlights the importance of adaptive and flexible trial designs to meet regulatory and post-regulatory requirements in the pharmaceutical field.
In her role overseeing all development phases within a Therapeutic Area, she has taken on the responsibility of evaluating Real-World Evidence (RWE), which has become one of her key research topics. Three years ago, she joined the Statistical Methodology Group at Novartis to lead a team focused on a project that integrates evidence from randomized controlled trials (RCTs) with clinical practice.
